(Reuters) – The EU on Friday approved U.S.-based Biomarin Pharmaceutical Inc’s treatment for one of the most common forms of dwarfism, the first such approval in the region for a therapy to treat the underlying cause of achondroplasia, the company said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
